Cozad Asset Management Inc. Has $3.59 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Cozad Asset Management Inc. trimmed its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,417 shares of the biopharmaceutical company’s stock after selling 34 shares during the quarter. Cozad Asset Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $3,592,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. SteelPeak Wealth LLC increased its position in Regeneron Pharmaceuticals by 173.0% during the 2nd quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company’s stock worth $1,148,000 after purchasing an additional 692 shares in the last quarter. Atria Investments Inc increased its position in Regeneron Pharmaceuticals by 12.2% during the 1st quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company’s stock worth $8,317,000 after purchasing an additional 941 shares in the last quarter. Tri Locum Partners LP increased its position in Regeneron Pharmaceuticals by 104.5% during the 2nd quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company’s stock worth $18,410,000 after purchasing an additional 8,949 shares in the last quarter. Tidal Investments LLC increased its position in Regeneron Pharmaceuticals by 16.8% during the 1st quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company’s stock worth $4,774,000 after purchasing an additional 711 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC acquired a new position in Regeneron Pharmaceuticals in the 1st quarter valued at approximately $1,232,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 7.48% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on REGN. Wells Fargo & Company decreased their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a research report on Tuesday, October 22nd. Royal Bank of Canada decreased their price target on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. Cantor Fitzgerald restated a “neutral” rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Truist Financial decreased their price target on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Finally, StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday. One research analyst has rated the stock with a sell rating, four have issued a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $1,092.62.

Regeneron Pharmaceuticals Stock Down 1.5 %

Shares of NASDAQ REGN opened at $816.65 on Thursday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $783.57 and a 12-month high of $1,211.20. The firm has a market cap of $90.03 billion, a PE ratio of 20.21, a P/E/G ratio of 3.17 and a beta of 0.15. The company’s fifty day simple moving average is $1,035.92 and its 200 day simple moving average is $1,038.36. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.